We promote the understanding of assessment and access processes for life science products to support the development and adoption of innovative treatments
Cost-effectiveness thresholds were introduced to make reimbursement decisions more consistent. They now affect net prices, managed access terms, launch decisions and wider medicines policy.
A new public-statistics study uses official reimbursement and rebate data to show how high-cost hospital-linked medicines are shaping French expenditure growth.
